The patient, classified as Child-Pugh class B, was hospitalized with severe hepatitis. During the hospitalization, she developed a catheter-related bloodstream infection and persistent low back pain. Investigators identified the spinal infection through imaging, metagenomic next-generation sequencing and pathological tests. The report states that the diagnostic process was complex, while the literature review found that spinal infections in people with cirrhosis can involve diverse pathogens and that clinical manifestations may be nonspecific, contributing to diagnostic delays.

Management included antibacterial and antifungal treatment, followed by lumbar debridement, bone graft fusion and internal fixation. The patient subsequently showed significant improvement in back pain, normalization of inflammatory markers and overall clinical recovery. These observations describe the course of this individual case; the report does not establish comparative treatment effectiveness or provide evidence from a larger patient series.

The authors characterized the case as clinically rare and diagnostically challenging. In the abstract, they note that the study is a single case report accompanied by a literature review, so its scope is limited to one patient and the findings summarized from the cited literature. They concluded that cirrhosis complicated by mixed bacterial and fungal spinal infection can present with nonspecific symptoms and requires a difficult diagnostic process. The report’s broader clinical advice about considering spinal infection in cirrhotic patients with unexplained back pain, using MRI and etiological testing, and providing individualized antimicrobial treatment and surgery when necessary comes from the authors’ conclusion rather than from comparative clinical outcomes.

Subject of Research: A single-patient case report and literature review of mixed bacterial and fungal spinal infection in a woman with hepatitis C-related cirrhosis.

Article Title: Lactococcus lactis and Aspergillus fumigatus co-infection in cirrhotic patients: a case study and literature review

Article References: Li, Y., Li, S., Hou, Y., & Huang, Q. (2026). Lactococcus lactis and Aspergillus fumigatus co-infection in cirrhotic patients: a case study and literature review. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14461-6

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14461-6

Keywords: case report, liver cirrhosis, spinal infection, spondylitis, Lactococcus lactis, Aspergillus fumigatus, mNGS, lumbar surgery, Lactococcus, lactis, Aspergillus, fumigatus

The study, published in BMC Medical Imaging, enrolled 143 patients with either hepatitis B virus-related cirrhosis or schistosomiasis-related cirrhosis across three institutions between August 2019 and December 2021. Rather than asking radiologists to eyeball the scans, the researchers applied a technique called radiomics, which converts medical images into hundreds of quantitative features that capture subtle patterns of texture, shape, and intensity invisible to the human eye. These features were extracted from non-contrast CT images of the liver, meaning patients did not need contrast agents or additional scanning procedures beyond the imaging they would receive anyway.

To build a reliable signature from this high-dimensional feature space, the team used a two-stage statistical pipeline. First, minimum redundancy maximum relevance, or mRMR, screened the extracted features to identify those most informative about the disease etiology while avoiding redundant overlap. Then, least absolute shrinkage and selection operator regression, known as LASSO, further compressed the feature set and assigned each surviving feature a weighted coefficient, producing a single composite score called the Rad-score. This score summarizes the aggregate imaging fingerprint of each patient’s liver into one number that reflects the probability of one etiology versus the other.

The results were striking. The Rad-score was significantly lower in patients with hepatitis B virus-related cirrhosis than in those with schistosomiasis-related cirrhosis, with P values below 0.001 in both the training and internal validation cohorts. This suggests that the two diseases leave measurably different traces in the texture and structure of liver tissue on plain CT scans, traces that the algorithm can detect even when the overall appearance of cirrhosis looks similar. Schistosomiasis-related fibrosis, which concentrates around portal vein branches and produces a distinctive periportal pattern, appears to generate a different radiomic texture than the diffuse parenchymal damage typical of chronic viral hepatitis.

Building on the imaging signature, the researchers developed three diagnostic models using multivariable logistic regression: a clinical model based on patient characteristics alone, a radiomics model based on the Rad-score alone, and an integrated clinical-radiomics model combining both sources of information. The integrated model proved the strongest performer, achieving an area under the receiver operating characteristic curve, or AUC, of 0.990 in the training cohort, 0.920 in the internal validation cohort, and 0.782 in the external validation cohort. An AUC of 0.990 means the model could correctly rank a randomly chosen pair of patients, one from each disease group, nearly every time in the training data.

Performance naturally declined when the model was tested on data from institutions it had never seen, dropping to 0.782 in external validation, a pattern common in radiomics research where scanner settings, patient demographics, and imaging protocols differ across sites. Notably, however, both the radiomics and integrated models showed more consistent performance across the internal and external validation cohorts than the clinical model alone, suggesting that the imaging features carry transferable information about disease etiology that clinical variables by themselves do not capture. The integrated model also demonstrated the greatest overall clinical utility in decision curve analysis, a method that evaluates whether a model would benefit patients across a realistic range of diagnostic thresholds rather than at a single arbitrary cutoff.

Calibration curves further confirmed that the integrated model’s predicted probabilities tracked well with observed disease frequencies, an important property for clinical deployment because a model that is accurate on average but poorly calibrated can mislead individual treatment decisions. Decision curve analysis complemented this by showing that, across a broad span of threshold probabilities, acting on the integrated model’s predictions would yield more net benefit than treating all patients as having one etiology or the other, or than relying on the clinical model in isolation.

The clinical implications are considerable for endemic regions where schistosomiasis and hepatitis B coexist. Accurate etiological differentiation matters because the two conditions differ substantially in pathogenesis, clinical management, and prognosis. Schistosomiasis-related cirrhosis may respond to antiparasitic therapy and management of portal hypertension, while hepatitis B-related cirrhosis requires antiviral treatment and surveillance for hepatocellular carcinoma. A non-invasive tool that can be applied to CT scans already obtained for routine care, interpreted alongside standard clinical and laboratory evaluation, could spare patients unnecessary biopsies and accelerate appropriate treatment pathways.

The authors emphasize that their model is intended as a complementary imaging tool rather than a replacement for clinical judgment, and that further prospective multicenter studies are warranted to validate its utility before widespread adoption. The retrospective design, the relatively modest sample size of 143 patients, and the performance drop in external validation all point to the need for larger, prospectively designed trials. Nevertheless, the study adds to a growing body of evidence that quantitative image analysis can extract diagnostic information from routine scans that far exceeds what conventional radiological interpretation provides, potentially transforming how etiological assessment of cirrhosis is conducted in resource-limited endemic settings.

Subject of Research: CT-based radiomics combined with clinical features for non-invasive differentiation of hepatitis B virus-related and schistosomiasis-related cirrhosis

Article Title: CT-based radiomics combined with clinical features for non-invasive differentiation of hepatitis B and schistosomiasis cirrhosis: a multicenter study

Article References: Tong, J., Xu, X., Hu, F., Wang, Z., Ma, L., Li, J., Li, X., Yang, Z., & Xia, X. (2026). CT-based radiomics combined with clinical features for non-invasive differentiation of hepatitis B and schistosomiasis cirrhosis: a multicenter study. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02693-6

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02693-6

Keywords: radiomics, hepatitis B virus, schistosomiasis, liver cirrhosis, computed tomography, clinical-radiomics model, non-invasive diagnosis, machine learning, BMC Medical Imaging, multicenter study, CT-based, combined

Infections are among the most feared complications of advanced liver disease. When cirrhosis decompensates—through ascites, variceal bleeding, or hepatic encephalopathy—an infection is frequently the trigger or the accelerant. Bacterial translocation from the gut, impaired clearance of microbes by the reticuloendothelial system, and systemic inflammation converge to make cirrhotic patients exquisitely susceptible. Once an infection takes hold, the clinical trajectory often steepens sharply: in the Graz cohort, patients who developed an infection faced a mortality rate of 41 percent during follow-up. Identifying who is most vulnerable before the first fever appears is therefore a central clinical challenge, and the standard prognostic instruments—the Model for End-stage Liver Disease (MELD) score and the Child-Pugh classification—capture liver dysfunction but say little about immune competence.

HDL and apolipoprotein A-I bring exactly that missing dimension. Far from being a passive cholesterol shuttle, HDL is an active participant in innate immunity. It binds and neutralizes lipopolysaccharide, the toxic lipid component of Gram-negative bacterial cell walls, sequestering it away from the lipopolysaccharide-binding protein pathway that would otherwise amplify inflammatory signaling. Apolipoprotein A-I, which constitutes roughly 70 percent of HDL protein mass, contributes to this endotoxin-binding capacity and also modulates leukocyte behavior, supporting anti-inflammatory polarization of monocytes and macrophages. In chronic liver disease, both the quantity and the quality of HDL deteriorate: hepatic lipase and lecithin-cholesterol acyltransferase activity decline, apolipoprotein composition shifts, and the particle becomes pro-inflammatory rather than protective. Low HDL-C in cirrhosis is thus not merely a metabolic footnote but a potential readout of a compromised endotoxin-buffering system.

The Graz team, led by Florian Rainer, Markus Trieb, Angela Horvath, Gunther Marsche, Vanessa Stadlbauer, and Rudolf E. Stauber, designed the study as a single-centre cohort with a built-in temporal validation. A total of 311 patients with cirrhosis were enrolled, divided into a training cohort of 225 and a separate validation cohort of 86 recruited later. At baseline, researchers measured HDL cholesterol and apolipoprotein A-I alongside standard clinical chemistry. The primary endpoint was strictly defined: an infection requiring antibiotic therapy within 12 months. Infections occurred in 24 percent of the training cohort and 31 percent of the validation cohort, consistent with the substantial infectious burden known to accompany decompensated cirrhosis.

The statistical machinery applied was appropriately rigorous for a prognostic biomarker study. Cox regression models estimated the association between baseline biomarker levels and time to first infection, producing both crude and adjusted hazard ratios. Discriminative performance was quantified with Harrell’s C-index and with censoring-adjusted, time-dependent receiver operating characteristic analyses at the 12-month horizon. When HDL-C or apoA-I were added to the MELD score in the training cohort, both biomarkers significantly improved discrimination, and the combined biomarker models achieved higher C-indices and numerically higher 12-month area-under-the-curve values than MELD or Child-Pugh alone. In other words, the lipid markers carried prognostic information that the established liver scores did not.

From the training data, the team derived exploratory cut-offs: HDL-C below 40.4 milligrams per deciliter and apoA-I below 98.5 milligrams per deciliter identified groups with higher infection risk. These thresholds sit close to conventional clinical boundaries for low HDL, suggesting that the biomarker signal is not confined to extreme values but operates across the range routinely seen in cirrhotic patients. Lower levels of both markers were significantly associated with infection risk in both the training and validation cohorts, lending the core association a degree of robustness that single-cohort findings often lack.

The validation results, however, temper the enthusiasm. In the 86-patient temporal validation cohort, the discriminative performance of the biomarker-based models attenuated: they performed comparably to, rather than better than, the established MELD and Child-Pugh scores. This pattern is familiar in biomarker research. Models fitted to one dataset routinely shrink when applied to another, as overfitting, cohort composition, disease stage, and chance all conspire to erode apparent performance. The Graz investigators are explicit about this limitation: the findings support HDL-C and apoA-I as candidate prognostic biomarkers of infection susceptibility, but external validation in independent centres and prospective assessment of clinical utility are required before any recommendation for routine use can be made.

The mechanistic interpretation is where the story becomes scientifically rich. Cirrhosis dismantles the liver’s role as the body’s endotoxin filter. Portal hypertension widens the gut mucosal barrier, allowing bacterial products to translocate into portal blood, while the diseased hepatic reticuloendothelial system clears them less efficiently. HDL, by binding lipopolysaccharide and promoting its delivery to the liver for detoxification, acts as a circulating countermeasure. When HDL-C and apoA-I fall—whether through impaired hepatic synthesis, malnutrition, inflammation-driven catabolism, or qualitative particle dysfunction—the endotoxin-buffering reserve thins. The result is a patient whose plasma can no longer adequately sequester bacterial toxins, priming the innate immune system for the exaggerated inflammatory responses that characterize spontaneous bacterial peritonitis and sepsis in cirrhosis. Low HDL in this context may be a biomarker of both a depleted defense and a liver too sick to rebuild it.

There are also therapeutic implications, though the authors are careful to label them as requiring dedicated investigation. HDL-raising interventions exist—niacin, statins, CETP inhibitors, lifestyle measures—but their history in cardiology is cautionary: raising HDL-C pharmacologically has repeatedly failed to translate into clinical benefit, and the qualitative functionality of the particle matters as much as its concentration. In cirrhosis, the relevant question is not whether HDL-C can be numerically elevated but whether the endotoxin-binding and immune-modulatory functions of apoA-I can be restored. Apolipoprotein A-I infusions and HDL-like synthetic particles have shown endotoxin-neutralizing capacity in experimental sepsis models, offering a speculative route from biomarker to therapy. Whether such approaches could reduce infection risk in cirrhotic patients remains an open question that no current evidence answers.

What the Graz study delivers now is a candidate risk stratification tool built from two inexpensive, widely available laboratory measurements. A clinician seeing a decompensated cirrhotic patient with HDL-C under 40 milligrams per deciliter and apoA-I under 100 milligrams per deciliter gains a signal—beyond MELD and Child-Pugh—that this individual sits in a higher infection-risk stratum and may warrant heightened surveillance, earlier diagnostic workup for subtle infection, and closer follow-up. The association between infection and a 41 percent mortality rate during follow-up underscores the stakes. Until external validation confirms the cut-offs and prospective trials demonstrate that acting on them improves outcomes, HDL-C and apoA-I remain promising candidates rather than established instruments. But the study adds a compelling chapter to the growing recognition that lipoproteins are not just cardiovascular currency—they are immunological actors whose decline in cirrhosis may announce, months in advance, the infections that decompensate and kill.

Subject of Research: Lipoprotein-related biomarkers HDL-C and apoA-I predict infection risk in patients with liver cirrhosis

Article Title: Lipoprotein-related biomarkers HDL-C and apoA-I predict infection risk in patients with liver cirrhosis

Article References: Rainer, F., Trieb, M., Horvath, A., Douschan, P., Scharnagl, H., Heinemann, Á., Marsche, G., Stadlbauer, V., & Stauber, R. E. (2026). Lipoprotein-related biomarkers HDL-C and apoA-I predict infection risk in patients with liver cirrhosis. Scientific Reports. https://doi.org/10.1038/s41598-026-74841-5

Image Credits: AI Generated

DOI: 10.1038/s41598-026-74841-5

Keywords: liver cirrhosis, HDL cholesterol, apolipoprotein A-I, biomarkers, infection risk, immunology, Scientific Reports, Lipoprotein-related, HDL-C, apoA-I, predict, infection

The research team, led by surgeons from Zhongshan People’s Hospital and Shenzhen Longhua District People’s Hospital in China, analyzed 383 patients who underwent radical resection of solitary HCC with tumors no larger than 5 centimeters. Every patient had preoperative CTC testing performed three days before surgery, using a technique that combines negative immunomagnetic enrichment with immunofluorescence in situ hybridization. In this method, magnetic beads coated with antibodies against CD45—a marker found on white blood cells—are used to strip away leukocytes from a 5-milliliter peripheral blood sample, enriching the rare malignant cells that have entered the bloodstream through epithelial-mesenchymal transition. The remaining cells are then fixed on slides, hybridized with fluorescent probes targeting the centromeres of chromosomes 1 and 8, stained with DAPI, and counted under a fluorescence microscope. A count of one or more CTCs per sample defined CTC-positive status, a threshold the researchers found correlated strongly with microvascular invasion (MVI), the pathological hallmark of tumor aggressiveness in HCC.

The clinical significance of MVI cannot be overstated. From a pathological standpoint, an HCC lesion is not merely the visible tumor mass; it includes microscopic tumor cell nests invading nearby blood vessels, which a narrow resection margin cannot reliably remove. Previous studies have shown that wide margins reduce early postoperative recurrence in patients with MVI, but offer no such advantage in those without it. The problem has been that MVI can only be confirmed definitively after surgery, when the specimen is examined under a microscope—far too late to guide the surgeon’s hand. Imaging-based prediction models exist, but they lack standardized criteria and show limited accuracy, while subjective assessments such as tumor capsule integrity depend heavily on equipment quality and observer judgment. What the new study demonstrates is that CTC status, detectable in a simple blood draw, serves as a preoperative proxy for MVI, and when combined with tumor diameter measured on routine contrast-enhanced CT or MRI, it creates a decision framework that is both objective and minimally invasive.

The statistical architecture of the study was rigorous. All patients were stratified by tumor size (3 centimeters or less versus more than 3 centimeters) and CTC status (positive versus negative), then further divided by margin width—narrow margins defined as less than 1 centimeter and wide margins as 1 centimeter or more, based on the pathologist-reported shortest macroscopic distance from the tumor edge to the line of transection. Kaplan-Meier survival curves and log-rank tests compared recurrence-free survival (RFS) and overall survival (OS) between groups, while univariate and multivariate Cox regression models identified independent risk factors. A landmark analysis with a 24-month cutoff distinguished early from late recurrence, reflecting the understanding that early recurrences arise from residual microscopic disease while late recurrences more often represent de novo tumors in the diseased liver.

The results revealed a striking stratified effect. In the entire cohort, both tumor diameter and CTC status emerged as independent predictors of RFS and OS. But when the researchers drilled into tumor-size subgroups, something unexpected appeared. For patients with tumors 3 centimeters or smaller—179 patients in total—margin width had no effect on RFS or OS, regardless of CTC status. The MVI rate in this group was only 14.5 percent, and based on multicenter pathological data suggesting that MVI lesions extending more than 1 centimeter from the main tumor account for roughly 28 percent of all MVI in small HCC, the researchers calculated that MVI beyond the 1-centimeter threshold likely occurs in fewer than 4 percent of these patients. In other words, a narrow margin is almost always sufficient to clear the microscopic disease in small tumors, and pursuing wider excision offers no survival benefit while sacrificing liver tissue that cirrhotic patients need to preserve.

The picture changed dramatically for patients with tumors larger than 3 centimeters—204 patients in this subgroup. Here, the MVI rate jumped to 43 percent, consistent with prior findings that tumor size predicts both the incidence and the extent of vascular invasion. When the researchers stratified this group by CTC status, the effect of margin width split cleanly. Among CTC-negative patients with larger tumors, narrow and wide margins produced comparable RFS and OS, with no statistically significant difference. But among CTC-positive patients with tumors exceeding 3 centimeters, wide margins yielded significantly better RFS and OS than narrow margins. Moreover, the landmark analysis showed that wide margins in this CTC-positive subgroup specifically reduced early postoperative recurrence—recurrence within 24 months—while having no effect on late recurrence. This finding aligns precisely with the biological mechanism: early recurrences stem from minimal residual disease left behind at the resection margin, and in patients whose tumors are both large and shedding malignant cells into the bloodstream, that residual burden is substantial enough that only a wider excision can remove it.

The correlation between CTC status and MVI held across both tumor-size groups, reinforcing the biological plausibility of the framework. In patients with tumors 3 centimeters or smaller, the CTC-positive rate was 14.5 percent, and CTC-positive status correlated with MVI at a statistically significant level. In the larger-tumor group, the CTC-positive rate rose to 43.1 percent, and the correlation with MVI was even stronger. Notably, CTC status showed no significant association with other clinicopathological variables, including alpha-fetoprotein levels and tumor differentiation grade, suggesting that it captures a distinct dimension of tumor biology—specifically, the propensity for vascular invasion and hematogenous dissemination—that traditional serum markers and histological grading do not fully reflect.

The study’s authors frame their findings within the broader concept of precision medicine in hepatobiliary surgery. By identifying patients who do not need wide margins—those with small tumors regardless of CTC status, and those with larger tumors that are CTC-negative—surgeons can preserve more functional liver parenchyma, reducing the risk of postoperative liver failure and increasing the option of repeat resection or other multimodal therapies if recurrence does occur. Conversely, for the smaller subset of patients with large, CTC-positive tumors, the data argue for pursuing wide margins, or alternatively, for using preoperative adjuvant therapy to reduce tumor burden before attempting an extended resection. Both variables—CTC count from a peripheral blood draw and tumor diameter from standard cross-sectional imaging—are available before the operation, are objective, and involve minimal patient discomfort, making the framework readily implementable in clinical practice without specialized equipment beyond the CTC detection platform.

The researchers acknowledge important limitations. The retrospective design carries inherent biases and confounding factors that only a prospective study with a larger sample size can eliminate. The cohort was overwhelmingly Chinese and hepatitis B virus-related, raising questions about whether the conclusions apply to non-Asian populations or to patients with hepatitis C-related or alcohol-related HCC. CTC counts may fluctuate over time within the same patient, introducing temporal heterogeneity. The median follow-up of 30 months, while adequate for capturing early recurrence patterns, is insufficient for robust long-term overall survival conclusions beyond five years. And the cost of CTC detection remains high in some regions, though the authors expect this to decrease as detection methods improve. The findings also apply specifically to patients with solitary tumors no larger than 5 centimeters, the population in which the resection margin dilemma is most acute.

Despite these caveats, the study represents a meaningful advance in a field where the optimal margin width has been debated for decades without consensus. Previous attempts to stratify patients by tumor size alone produced contradictory results, with some groups reporting survival benefits from wide margins across all tumor diameters and others, including a well-known Hong Kong study, finding no benefit in any subgroup. By adding CTC status as a second, biologically grounded variable, the researchers have created a two-parameter decision tool that resolves those contradictions and matches surgical aggressiveness to the actual risk of microscopic residual disease. For a cancer that kills nearly 800,000 people each year, and where the difference between a narrow and a wide margin can determine whether a patient keeps enough liver to survive the operation—or enough liver to undergo a second operation if the tumor returns—that kind of preoperative clarity is not just a statistical finding. It is a roadmap for safer, more individualized liver cancer surgery.

Subject of Research: Combined analysis of preoperative circulating tumor cells status and tumor size to guide width of resection margin for solitary hepatocellular carcinoma

Article Title: Combined analysis of preoperative circulating tumor cells status and tumor size to guide width of resection margin for solitary hepatocellular carcinoma

Article References: Xie, J., Luo, Q., Huang, D., Xia, F., Wu, Z., Zhou, W., Zhang, Q., Tian, F., Liu, C.-Y., Xu, Z., Jiao, X.-T., Zhang, W.-Q., Ali, M., Zhou, Y., & Gao, H. (2026). Combined analysis of preoperative circulating tumor cells status and tumor size to guide width of resection margin for solitary hepatocellular carcinoma. Frontiers in Oncology, 16, Article 1810914. https://doi.org/10.3389/fonc.2026.1810914

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1810914

Keywords: Combined, analysis, preoperative, circulating, tumor, cells, status, size, guide, width, resection, margin

Chronic infection with HBV and HCV has long been recognized as the dominant driver of liver cirrhosis and hepatocellular carcinoma worldwide. Both viruses establish persistent infections in the liver, and over years to decades the resulting chronic inflammation, fibrosis, and cirrhosis create the cellular environment in which malignant transformation becomes increasingly likely. Because the interval between infection and cancer development is so long, the effects of public health interventions targeting viral transmission can take generations to become fully visible in cancer statistics. Japan’s experience offers an unusually clear view of this delayed cascade, because the country implemented systematic countermeasures in successive waves beginning in the 1970s and maintained them through legal, financial, and clinical frameworks into the present decade.

The review traces the architecture of Japan’s response in three broad phases. From the 1970s onward, the country focused on blood safety and on reducing healthcare-associated transmission, measures that curtailed two of the most efficient routes of HBV and HCV spread. From 1986 onwards, Japan introduced prevention of mother-to-child transmission of HBV, an intervention with profound intergenerational consequences given that infection at birth carries the highest risk of chronicity. From the 2000s onwards, hepatitis control was institutionalized through dedicated legal and financial frameworks, alongside expanded access to antiviral treatment, allowing large numbers of chronically infected individuals to be identified, monitored, and cured or suppressed.

To assess the population-level impact of these measures, the researchers searched the PubMed database for peer-reviewed articles related to HCC, liver cancer, viral hepatitis, liver cirrhosis, and Japan published between January 1970 and January 2026. They supplemented this with manual searches of government reports, incorporated data from their own Epidemiological Research Group on Viral Hepatitis and its Long-term Course (VH-Epi), and drew on national vital statistics together with multiple large-scale surveillance and statistics databases. This combination of peer-reviewed literature, official registries, and long-running cohort data allowed the team to reconstruct trends in infection prevalence, incidence, and cancer mortality across the full arc of the national program.

The prevalence data reveal a striking decline across every population examined. Among first-time blood donors, a group generally regarded as a healthy cross-section of society, the proportion positive for hepatitis B surface antigen (HBsAg), the marker of active HBV infection, fell from 0.63 percent in 1995–2000 to 0.13 percent in 2017–2021. Over the same period, the proportion positive for HCV antibody, the marker of HCV exposure, fell from 0.49 percent to 0.16 percent. Among residents aged 40 years and older attending health checkups, HBsAg positivity declined from 1.16 percent in 2002 to 0.55 percent in 2021, while anti-HCV positivity fell from 1.16 percent to 0.21 percent. Newly acquired infections in blood donors have reached historically low levels, at 2.38 per 100,000 person-years for HBV and 0.4 per 100,000 person-years for HCV.

One of the most consequential findings concerns the youngest generation of mothers. Among pregnant women born in or after 2000, HBsAg-positive individuals have become extremely rare, a pattern Akita attributes directly to the mother-to-child transmission prevention program introduced in 1986. Because chronic HBV infection acquired at birth is the strongest risk factor for lifelong viral persistence and eventual HCC, the near-disappearance of HBsAg positivity in this birth cohort represents an intergenerational protective effect that will continue to propagate through the population as these women and their children age. It illustrates how a single well-targeted intervention, sustained over decades, can reshape the infection landscape for generations that were never directly exposed to the pre-intervention epidemiology.

The mortality data tell an equally compelling story. Long-term trends in cancer-specific mortality in Japan between 1958 and 2022 show that liver cancer mortality, which includes both viral-related and non-viral-related disease, rose steadily until the early 2000s and has subsequently declined. This trajectory contrasts sharply with several other major cancers, including pancreatic, lung, and colon cancers, for which mortality has continued to increase over comparable periods. The timing of the liver cancer downturn is consistent with the long natural history of viral hepatitis: the transmission reductions of the 1970s and 1980s, followed by treatment scale-up from the 2000s, have now translated into falling cancer deaths decades later.

As viral hepatitis-related HCC has declined, the relative composition of liver cancer causes in Japan has shifted in a way that would have seemed implausible a generation ago. The proportion of HCC deaths attributed to non-viral causes rose from 6.8 percent in 1992 to 56.0 percent in 2019. The review emphasizes that this shift largely reflects the substantial decline in viral hepatitis-related HCC rather than a comparable increase in the absolute burden of non-viral disease. In other words, the denominator has changed: viral hepatitis no longer dominates the country’s liver cancer mortality, and non-viral etiologies now account for more than half of HCC deaths. The principal non-viral contributors are alcohol-related liver disease and metabolic dysfunction-associated steatotic liver disease (MASLD), the latter reflecting the growing global prevalence of obesity, diabetes, and metabolic syndrome as drivers of chronic liver injury.

The transition does not mean the hepatitis problem is solved. The review identifies several high-risk populations in whom viral hepatitis remains an important concern, including persons who inject drugs, men who have sex with men, migrants from regions where HBV is endemic, and incarcerated populations. Reaching these groups with testing, linkage to care, and prevention services remains a central challenge as Japan moves toward the World Health Organization’s 2030 elimination targets, which call for dramatic reductions in new infections and deaths relative to a 2015 baseline. Maintaining the gains already achieved, through continued surveillance, blood safety, vaccination coverage, and treatment access, is described as essential even as the epidemiological center of gravity shifts.

The authors frame their findings as transferable lessons for other countries pursuing viral hepatitis elimination. Japan’s experience demonstrates that phased interventions, beginning with transmission control, extending to vertical transmission prevention, and culminating in legally anchored, funded treatment programs, can produce measurable population-level declines in infection prevalence and, with an appropriate time lag, in virus-associated cancer mortality. It also demonstrates that success creates new obligations: as Akita notes, the next step is to achieve and sustain viral hepatitis elimination while adapting liver cancer prevention to the country’s changing disease landscape. For Japan, that means building prevention and early-detection strategies around alcohol-related liver disease and MASLD, while for countries earlier in the elimination pathway, the Japanese trajectory provides both a roadmap and a preview of the epidemiological transition that successful control will eventually bring.

Subject of Research: Long-term national viral hepatitis control and the epidemiological transition of liver cancer mortality in Japan

Article Title: Long-term viral hepatitis control and changing patterns of liver cancer mortality in Japan

Article References: Long-term viral hepatitis control and changing patterns of liver cancer mortality in Japan. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: hepatitis B, hepatitis C, hepatocellular carcinoma, liver cancer, Japan, viral hepatitis elimination, MASLD, mother-to-child transmission, epidemiological transition, public health policy, antiviral treatment, liver cirrhosis

The team built their system around a three-dimensional convolutional neural network known as 3D-ResNet18, an architecture that extends the classic residual network design into volumetric imaging. Rather than analyzing a single slice, the model ingests entire CT series as three-dimensional blocks of voxels, allowing it to recognize patterns of enhancement that unfold across the liver, spleen, pancreas, and major vessels. The network was trained on 3,129 CT series drawn from 1,160 patients, with each series labeled as one of four contrast phases: noncontrast, early arterial, late arterial, or portal venous. This four-way classification task is harder than it sounds, because the boundary between early and late arterial enhancement is a moving target defined by subtle differences in the brightness of the aorta, the hepatic arteries, and the liver parenchyma.

Performance was assessed in two stages. On an internal test set of 710 patients, the model achieved F1 scores of 1.00 for noncontrast series, 0.92 for early arterial phase, 0.88 for late arterial phase, and 0.98 for portal venous phase. The F1 score, which balances precision and sensitivity into a single number, reflects how reliably the model both finds every instance of a phase and avoids mislabeling other phases as that one. A perfect 1.00 for noncontrast scans is unsurprising, since unenhanced images look radically different from contrast-enhanced ones, but the 0.88 for late arterial phase shows that the early-to-late arterial boundary remains the most confusable transition even for a machine. Among five candidate models evaluated, 3D-ResNet18 achieved the highest macro-averaged F1 score on the internal test set, 0.943, with a 95 percent confidence interval of 0.930 to 0.954.

Crucially, the researchers did not stop at internal validation, a step where many medical AI studies quietly falter. They tested the algorithm on an external dataset, the WAW-TACE collection of 233 patients, reformulated as a three-category task that merged early and late arterial phases into a single arterial class. On this unseen data the model held up remarkably well, with F1 scores ranging from 0.96 to 0.99 across the three categories. External validation of this kind is the gold standard for demonstrating that a network has learned generalizable features of contrast enhancement rather than quirks of one hospital’s scanners or protocols. The authors are careful to note, however, that the fine-grained discrimination between early and late arterial phases was not itself validated externally, an honest caveat that tempers the headline numbers.

Interpretability was addressed with gradient-weighted class activation mapping, or Grad-CAM, a technique that highlights the image regions most responsible for the network’s decision. The resulting heat maps showed that the model concentrated its attention on vascular structures and enhancing parenchyma, exactly the anatomical features a trained radiologist would inspect to determine contrast phase. This alignment between machine attention and clinical reasoning matters because a black-box classifier that happened to key on irrelevant artifacts could not be trusted to audit protocols. Here, the network appears to have learned the physiology, not the noise.

The second half of the study pivots from engineering to epidemiology. Using logistic regression, the team asked which patient factors predicted a specific timing failure: capturing an early arterial phase image when a late arterial phase scan was intended. This mismatch matters clinically, because late arterial phase imaging is deliberately timed to show both enhanced arteries and early portal venous filling, a window that is valuable for detecting hypervascular tumors and characterizing liver lesions. If the scan fires too early, the radiologist receives an image that looks plausible but lacks the expected enhancement pattern, potentially degrading lesion detection and quantitative measurements.

The results were striking. Patients older than 60 years had 1.854 times the odds of early arterial capture compared with younger patients, with a P value of 0.001. Liver cirrhosis carried an odds ratio of 4.461, ascites an odds ratio of 2.598, and pancreatic cancer an odds ratio of 7.103, the latter two with P values of 0.001 and below 0.001 respectively. Each of these conditions plausibly alters cardiovascular hemodynamics. Cirrhosis distorts hepatic blood flow and is often accompanied by systemic vasodilation and a hyperdynamic circulation. Ascites changes intra-abdominal pressure and fluid distribution. Pancreatic cancer and its treatment can affect splanchnic circulation, and advanced age brings arterial stiffening that delays and distorts the contrast bolus. In other words, the very patients who most need precise tumor imaging are the ones whose bodies are least likely to conform to a fixed injection-to-scan delay.

The implication is that one-size-fits-all timing protocols, in which the scanner fires at a set number of seconds after contrast injection, may systematically disadvantage a substantial subgroup of patients. Modern scanners can employ bolus tracking, in which the software monitors the aorta in real time and triggers acquisition when enhancement crosses a threshold, but even these systems make assumptions about how quickly enhancement will progress from arterial to portal venous dominance. The study’s findings suggest that individualized timing strategies, potentially informed by patient characteristics such as age, liver status, and malignancy type, could reduce the rate of suboptimal phase capture. The authors are appropriately cautious, noting that such individualized approaches require prospective validation before clinical adoption.

Beyond the immediate clinical message, the work has practical applications in the booming field of radiomics and medical deep learning. Multiphase CT studies, which compare lesion appearance across noncontrast, arterial, and portal venous phases, depend on the assumption that each phase is correctly labeled. If a substantial fraction of arterial phase series are actually mistimed, downstream analyses that extract quantitative features from those images inherit the error. An automated phase auditor like this one could serve as a quality-control gate, flagging mistimed series before they contaminate research datasets or mislead radiologists. It could also support protocol auditing at the departmental level, giving imaging administrators a data-driven picture of how often their timing protocols succeed across different patient populations.

The study, conducted under institutional review board approval and published open access, was supported by the Sichuan Science and Technology Program. Its limitations are acknowledged by the authors themselves: the early-versus-late arterial distinction was not externally validated, and the associations with patient factors come from retrospective data that cannot prove causation. Still, the convergence of strong external performance, physiologically sensible attention maps, and clinically coherent risk factors makes this a compelling demonstration of what happens when machine learning is pointed not at diagnosis itself, but at the quiet infrastructure of imaging quality that diagnosis depends on. As AI increasingly reads our scans, studies like this one remind us that the machines can also grade the scans themselves, and in doing so, reveal the hidden variability of human bodies that no fixed protocol fully anticipates.

Subject of Research: Deep learning detection of suboptimal arterial phase timing in abdominal CT and associated patient factors

Article Title: Deep learning-based detection of suboptimal arterial phase timing in abdominal CT: prevalence and associated patient factors

Article References: Luo, G., Liu, J., Li, M., Lin, S., Huang, H., & Sun, H. (2026). Deep learning-based detection of suboptimal arterial phase timing in abdominal CT: prevalence and associated patient factors. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02905-z

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02905-z

Keywords: deep learning, abdominal CT, arterial phase timing, contrast-enhanced imaging, 3D-ResNet18, radiology, liver cirrhosis, pancreatic cancer, ascites, hemodynamics, Grad-CAM, protocol optimization

Hepatic fibrosis is the accumulation of excess extracellular matrix, chiefly collagen, that follows chronic liver injury from causes such as viral hepatitis, alcohol use, fatty liver disease, and cholestatic disorders. Left unchecked, it progresses to cirrhosis and dramatically raises the risk of hepatocellular carcinoma. At the center of the scarring process are hepatic stellate cells, quiescent vitamin A-storing cells that, when activated by inflammatory cues, transform into myofibroblast-like cells that pump out matrix proteins. The immune microenvironment surrounding these cells, particularly the behavior of macrophages, largely determines whether injury resolves or spirals into permanent scarring. Macrophages are famously plastic: they can polarize toward a classically activated M1 state, marked by production of tumor necrosis factor-alpha and interleukin-1 beta, or toward an alternatively activated M2 state, associated with transforming growth factor beta and tissue remodeling. Both extremes, paradoxically, can feed fibrosis, one by fueling inflammation and the other by driving matrix deposition.

What the new study adds is a nervous system connection to this immunological drama. The researchers began by examining liver tissue from cirrhotic and non-cirrhotic human subjects, with informed consent and ethical approval from Tangdu Hospital, and then modeled fibrosis in mice using two complementary approaches: repeated intraperitoneal injection of carbon tetrachloride, a hepatotoxin that causes oxidative injury, and a 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet, which induces cholestatic damage. Across both human samples and both mouse models, NPY levels rose in fibrotic livers. Crucially, the source of that NPY was not the liver cells themselves but intrahepatic sympathetic nerves, identified through markers such as tyrosine hydroxylase. The finding places the sympathetic nervous system, the branch that mediates fight-or-flight responses, in direct molecular contact with the liver’s immune landscape.

The team next asked which cells were listening. NPY signals through a family of G protein-coupled receptors, and the investigators mapped their distribution carefully. Two of them, NPY1R and NPY2R, were significantly increased in fibrotic liver and localized specifically to hepatic macrophages, while the related NPY4R and NPY5R did not show the same pattern. This receptor specificity matters, because it narrows a broad neuropeptide signal down to a defined cellular target and suggests that the macrophage is the critical relay station between sympathetic nerve activity and fibrogenesis.

To test causality rather than mere correlation, the researchers turned to genetics and gene silencing. In NPY-knockout mice subjected to the fibrosis protocols, liver injury, collagen deposition, and inflammation were all significantly reduced. Flow cytometry and molecular profiling of the animals’ macrophages revealed that the deletion suppressed both M1 and M2 polarization, indicating that NPY was not simply tipping the balance between the two states but amplifying the entire profibrotic immune program. When the team silenced NPY1R or NPY2R in the liver in vivo using adeno-associated virus vectors, the protective phenotype was recapitulated, confirming that the receptors were the necessary conduits for NPY’s fibrogenic effects.

The mechanistic heart of the paper lies in the downstream signaling dissection, performed in vitro with bone marrow-derived macrophages. The researchers found that NPY engages a PI3K-dependent cascade in both polarization directions, but the pathways diverge at a key kinase node. For M1 polarization, NPY acting through NPY1R and NPY2R activates the PI3K-PAK1-c-Jun axis, with c-Jun, a component of the AP-1 transcription factor complex, driving the inflammatory gene program. For M2 polarization, the signal instead flows through PI3K-PAK1 to RSK, a ribosomal S6 kinase, promoting the alternative activation program. Blocking the corresponding receptors or the downstream kinases pharmacologically in vitro abolished these effects, allowing the authors to draw a solid, experimentally validated map from neuropeptide to receptor to kinase to transcription factor to macrophage phenotype.

The final link in the chain connects macrophages back to stellate cells. Polarized macrophages release a cocktail of profibrotic cytokines, including TNF-alpha, IL-1 beta, TGF-beta, and platelet-derived growth factor BB, which are well-established activators of hepatic stellate cells. By supercharging both macrophage states, NPY effectively raises the volume of the profibrotic conversation between immune cells and matrix-producing cells. The authors are careful to distinguish what has been proven from what remains plausible: the receptor-PI3K-PAK1 cascades are experimentally validated, whereas a direct NPY effect on stellate cells and the precise macrophage-stellate cell crosstalk remain putative, unvalidated interactions in their model. That transparency is a useful reminder of where the science currently stands.

The therapeutic implications are considerable. Current antifibrotic options are limited, and most strategies target downstream consequences of injury rather than upstream regulatory circuits. If sympathetic nerve-derived NPY is a genuine driver of fibrogenesis, then NPY1R and NPY2R become attractive drug targets, and receptor antagonists, some of which have already been developed for metabolic and cardiovascular research, could in principle be repurposed or refined. The dual role of NPY in pushing macrophages toward both inflammatory and profibrotic states suggests that receptor blockade might dampen fibrosis through two mechanisms simultaneously. At the same time, the systemic importance of NPY in appetite regulation, vascular tone, and stress physiology means that any clinical strategy would need to navigate a narrow therapeutic window, likely favoring targeted delivery to the liver or selective peripheral receptor antagonism over systemic neuropeptide depletion.

The study also contributes to a rapidly growing appreciation of neuroimmune crosstalk in chronic disease. The idea that nerves do more than transmit sensation and regulate tone, that they actively sculpt local immune responses through neuropeptide release, has gained traction in fields ranging from intestinal inflammation to tumor immunology. This work extends that framework to the liver, an organ densely innervated at portal triads and richly supplied by sympathetic fibers, and identifies a concrete molecular itinerary by which neural input becomes fibrotic output. It raises provocative questions about whether chronic stress, which elevates sympathetic outflow and systemic NPY, might modulate fibrosis progression in patients, a hypothesis the current study does not directly test but which its findings make testable.

Caveats remain, as they do in any preclinical study. The mouse models, carbon tetrachloride injury and DDC diet, are established but imperfect proxies for the heterogeneous fibrotic diseases seen in clinics, and the human tissue analysis, while consistent with the animal data, is observational. Whether NPY receptor blockade can safely slow or reverse established fibrosis in patients will require medicinal chemistry, pharmacokinetics, and eventually clinical trials that this paper does not provide. Still, by connecting sympathetic nerves, macrophage polarization, PI3K-MAPK signaling, and stellate cell activation into a single coherent pathway, the Xi’an team has converted a diffuse suspicion that the nervous system matters in liver disease into a specific, targetable hypothesis. For the millions of people living with chronic liver disease worldwide, that specificity is precisely what the field needs.

Subject of Research: Neuroimmune signaling by neuropeptide Y in macrophage polarization and hepatic fibrosis

Article Title: NPY promotes macrophage polarization and hepatic fibrogenesis via PI3K/MAPK-dependent neuroimmune mechanisms

Article References: Lin, Q., Zheng, X., Dou, W., Bai, Q., Liang, S., Kou, Z., Guo, H., Ding, Y., Zhao, S., Wang, J., Yin, J., & Liu, Z. (2026). NPY promotes macrophage polarization and hepatic fibrogenesis via PI3K/MAPK-dependent neuroimmune mechanisms. Cellular and Molecular Life Sciences, 83(1), Article 346. https://doi.org/10.1007/s00018-026-06428-2

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06428-2

Keywords: neuropeptide Y, hepatic fibrosis, macrophage polarization, NPY1R, NPY2R, PI3K signaling, MAPK, sympathetic nervous system, hepatic stellate cells, liver cirrhosis, neuroimmune crosstalk, cytokines

The research, published in CVIR Oncology, focused on patients undergoing microwave ablation, a technique in which a needle-like antenna inserted into the tumor generates electromagnetic fields that heat and coagulate cancerous tissue. Thermal ablation and transarterial chemoembolisation, known as TACE, are both mainstays of hepatocellular carcinoma treatment and are included as first-line options for selected patients in the Barcelona Clinic Liver Cancer recommendations as well as in American, Asian-Pacific and European guidelines. Ablation is generally reserved for patients with three or fewer tumors no larger than three centimeters, while TACE serves patients with larger or more numerous tumors who are ineligible for transplantation. Because survival after TACE alone remains limited, clinicians have increasingly experimented with combining the two approaches, and several studies have shown that the combination improves overall survival, progression-free survival and local tumor control compared with chemoembolisation alone. What has been missing is any consensus on the optimal sequence and timing.

Two competing strategies dominate the field. In the TACE-first approach, embolising the hepatic arterial branches before ablation reduces the so-called heat-sink effect, in which flowing blood carries heat away from the tumor and shrinks the zone of destruction; blocking that flow first can enlarge the ablation zone. The alternative is to ablate first and follow with adjuvant TACE, a strategy motivated by the peri-ablational hyperemic response. The logic is elegant: the inflamed, hyperperfused tissue ringing the ablation cavity, with its increased blood flow, vascular permeability and reduced drug resistance, could act as a delivery corridor, allowing chemoembolic material loaded with cytotoxic drugs to reach vulnerable but potentially viable tumor cells lurking at the margin. Animal models had already demonstrated the existence of this hyperemic zone, including reports of erythrocyte congestion after thermal injury, but its temporal evolution in humans had never been systematically characterized.

To fill that gap, the Swedish team enrolled 38 patients scheduled for microwave ablation of primary liver tumors or metastases between February and October 2024 at their tertiary referral centre, ultimately analyzing 34 patients evenly split between those with cirrhosis and those without. All ablations were performed under general anesthesia in the angiography suite using Medtronic Emprint HP or Amica microwave systems under ultrasound guidance, with confirmation by cone-beam computed tomography. Each patient then underwent four contrast-enhanced ultrasound examinations at fixed intervals: immediately after the procedure, and again at two, six and twenty-four hours. The technique relies on microbubble contrast agents roughly the size of red blood cells, which are injected into a peripheral vein and tracked as they course through the liver, allowing repeated perfusion assessments without the radiation burden of repeated CT scans.

The analytical approach was as important as the imaging itself. Using dedicated quantification software, the researchers compared the mean linearized signal in the hyperemic zone immediately adjacent to the ablation cavity with the signal in normal liver parenchyma at matching depths, avoiding artifacts and shadowed regions. The result was a hyperemia-to-normal-liver ratio, or HTNL, expressing how many times more intensely perfused the reactive zone was than healthy tissue. Motion compensation algorithms corrected for respiratory movement, and the width of the hyperemic rim was measured on arterial-phase images in a joint consensus reading by three board-certified radiologists blinded to clinical information and time points. Statistical comparisons against baseline used pairwise Wilcoxon signed rank tests, with each patient serving as their own control.

The numbers were striking. Immediately after ablation, the hyperemic zone was perfused at 567.5 percent of normal liver intensity in the overall group, an almost sixfold arterial oversupply, with values of 464.8 percent in cirrhotic livers and 625.0 percent in non-cirrhotic ones. That peak proved transient. By two hours the overall group’s ratio had fallen by a median of 158.9 percentage points, by six hours the drop reached 283.8 points, and at twenty-four hours it stood at 270.9 points below baseline, with all changes statistically significant. The decline was steepest in the first six hours and then leveled off, suggesting the hyperemic response collapses rapidly and then plateaus at a lower intensity. Critically, the pattern held in both cirrhotic and non-cirrhotic patients, indicating that the vascular reactivity to thermal injury operates independently of the altered hepatic hemodynamics that cirrhosis produces.

The spatial dimension of the response told the same story. The hyperemic rim measured a median of twelve millimeters wide immediately after ablation in the overall group, ten millimeters in cirrhotic patients and fourteen in non-cirrhotic ones. Over the following day it shrank steadily, narrowing by two millimeters at two hours, three at six hours and five at twenty-four hours, with parallel trends in both patient subgroups. The portal venous phase, by contrast, showed only modest enhancement, around 181.8 percent at baseline in the overall group, and no meaningful temporal decline, which the authors interpret as strong evidence that the hyperemia is supplied principally by the hepatic artery rather than the portal vein. Some portal contribution or arterial recirculation of contrast through the inflamed area cannot be excluded, but the arterial signal dwarfs everything else.

These findings carry immediate implications for trial design. Because the hyperemic zone is widest and most intensely arterialized in the first hours after ablation, an ablation-first strategy followed by TACE would plausibly need to be executed within that early window to exploit the biology. Existing evidence on sequencing remains inconclusive: one study favored ablation followed by chemoembolisation, another found no difference by order, and crucially the intervals between the two treatments varied enormously across studies, meaning any timing-dependent advantage could have been washed out. By providing high temporal resolution of the hyperemic response in humans, the Swedish data give future combination trials a concrete physiological target: the first twenty-four hours after ablation, and arguably the first six.

The authors acknowledge limitations inherent to a real-world clinical study. Ultrasound is operator-dependent, mitigated here by a small number of experienced examiners, and the consensus approach to rim measurement, while pragmatic, suppresses inter-reader variability and precludes formal reproducibility analysis. Examination times, though closely approximating the intended intervals, could not always be identical, and ablation energy and duration were chosen for treatment benefit rather than standardized, though using each patient as their own control partially offsets that. Even so, the study’s strengths, repeated quantitative imaging without radiation exposure and objective software-based perfusion measurement, make the conclusion robust: the post-ablation hyperemia is arterially supplied, peaks immediately, and fades fast. For a treatment concept that has hovered between promise and practice for years, the clock has now been set, and the race to deliver drugs into that glowing ring of healing liver may finally have a schedule.

Subject of Research: Temporal characterization of peri-ablational hyperemia after microwave ablation of liver tumors using quantitative contrast-enhanced ultrasound

Article Title: Quantitative analysis of peri-ablational hyperemia after microwave ablation of liver tumors – exploring the timing for future combination therapies

Article References: Norström Svensson, M., Will, L., Östrand, E., Sartor, H., Tingstedt, B., Andersson, B., & Baubeta, E. (2026). Quantitative analysis of peri-ablational hyperemia after microwave ablation of liver tumors – exploring the timing for future combination therapies. CVIR Oncology, 2(1), Article 8. https://doi.org/10.1007/s44343-026-00040-8

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00040-8

Keywords: microwave ablation, peri-ablational hyperemia, hepatocellular carcinoma, transarterial chemoembolisation, contrast-enhanced ultrasound, liver tumors, thermal ablation, liver cirrhosis, combination therapy, interventional radiology, tumor ablation margin, hepatic perfusion

The research, led by Lubin Gou and Junqiang Lei of the First Hospital of Lanzhou University and Lanzhou University’s First Clinical Medical College, focused on patients with liver cirrhosis without overt hepatic encephalopathy, a stage abbreviated LC-nOHE. This is the window in which the disease has already compromised liver function but has not yet produced the confusion, disorientation, and personality changes that define overt hepatic encephalopathy. Understanding what happens in the brain during this silent phase is critical, because it may reveal the earliest opportunities for intervention before irreversible damage takes hold.

The team recruited 86 patients with liver cirrhosis but no overt encephalopathy, along with 62 healthy controls, and acquired high-resolution three-dimensional T1-weighted magnetic resonance images of every participant’s brain. From these scans, the researchers extracted the volume of the thalamus and three distinct measures of cortical shape: cortical thickness, sulcal depth, and fractal dimension, a measure of the complexity of the brain’s folded surface. Rather than examining these features in isolation, the investigators constructed structural covariance networks, mathematical maps in which brain regions are connected if their anatomical features covary across individuals. Such networks are widely used as proxies for coordinated maturational and degenerative processes, offering a window into how brain regions change together as a system.

The results were striking at multiple levels. Compared with healthy controls, patients with cirrhosis showed enlargement of the thalamus alongside a broad range of cortical morphological abnormalities. At the level of whole-network organization, the thalamo-cortical structural covariance networks of patients displayed reduced segregation, meaning the brain’s specialized modules were less clearly differentiated, and decreased integration, meaning efficient communication across the network was impaired. These two properties, segregation and integration, are hallmarks of a healthy, well-organized brain, and their simultaneous deterioration suggests a fundamental disruption of the architecture that supports cognition.

Zooming in on individual network nodes, the researchers found that the centrality of three regions was significantly reduced in patients: the thalamus itself, the supramarginal gyrus, and the insula. Each of these regions plays a recognizable role in the syndrome. The thalamus relays sensory and motor signals to the cortex and regulates consciousness and alertness; the supramarginal gyrus contributes to language and spatial cognition; and the insula supports interoception and awareness of the body’s internal state. Reduced centrality in these hubs indicates that they had lost influence within the network, becoming less connected to the rest of the brain’s structural architecture.

Perhaps the most clinically significant finding was the relationship between brain changes and liver function. The degree centrality of the thalamus was negatively correlated with liver function measures, meaning that the worse the liver was performing, the more the thalamus had lost its position within the brain’s structural network. This correlation ties the brain imaging directly to the severity of liver disease and supports the idea that the thalamus sits at the front line of the liver-brain axis, the pathway by which hepatic dysfunction, circulating toxins such as ammonia, and systemic inflammation are translated into neural injury.

To move beyond correlation and probe causality, the team applied a technique called causal analysis of structural covariance networks, or CaSCN. This approach examines how changes in one brain region’s morphology relate to changes in others across the progression of disease, allowing researchers to ask which region leads and which follows. The analyses demonstrated that thalamus volume had causal effects on the alterations of cortical morphology as liver dysfunction progressed. In other words, the data are consistent with a model in which the thalamus is not merely another victim of cirrhosis but an active driver, propagating structural changes outward to the cortical regions with which it is connected.

The study then took an unusual additional step: linking the brain imaging to genomics through imaging transcriptomics. Using normative gene-expression profiles from the Allen Human Brain Atlas, the researchers evaluated whether the spatial pattern of causal effects across the cortex overlapped with the spatial distribution of specific genes. It did. The pattern of causal path coefficients was spatially correlated with the expression of particular genes in the normative atlas, suggesting that the cortical regions most vulnerable to thalamus-driven change are also those with distinctive molecular signatures. Gene ontology analyses pointed toward enrichment in biological processes, molecular functions, and cellular components that may help explain why some cortical areas are preferentially affected while others are relatively spared.

Taken together, the findings provide a comprehensive, multilevel view of how the thalamo-cortical circuit becomes progressively vulnerable in liver cirrhosis before overt encephalopathy appears. The enlargement of the thalamus, consistent with processes such as edema or glial changes reported in prior literature on hepatic encephalopathy, appears to initiate a cascade that erodes the segregation and integration of the entire structural network, strips key hubs of their centrality, and reshapes the cortex in patterns governed partly by underlying gene expression. Because the thalamus’s network position tracks liver function, measures of thalamo-cortical network integrity could potentially serve as imaging biomarkers for identifying patients at risk of progressing to overt hepatic encephalopathy, enabling earlier monitoring and treatment.

The authors emphasize that these findings offer a potential mechanism-driven framework for understanding the earliest brain consequences of liver disease, one that connects organ function, network neuroscience, and transcriptomics within a single analytical pipeline. The work was supported by the Lanzhou University First Affiliated Hospital Foundation and the Science and Technology Department of Gansu Province, and it was approved by the Institutional Ethics Committee of the First Hospital of Lanzhou University. As cirrhosis continues to affect millions worldwide, studies like this one bring clinicians closer to detecting, and perhaps preventing, the neurological toll of liver disease before it announces itself in the clinic.

Subject of Research: Structural covariance network alterations of the thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy

Article Title: Multilevel structural covariance network alterations of thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy: associations with liver function and imaging transcriptomics

Article References: Gou, L., Ren, H., Xu, W., Gao, Y., Wang, S., Zhang, Y., Dou, Y., & Lei, J. (2026). Multilevel structural covariance network alterations of thalamo-cortical circuit in liver cirrhosis patients without overt hepatic encephalopathy: associations with liver function and imaging transcriptomics. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02790-6

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02790-6

Keywords: liver cirrhosis, hepatic encephalopathy, thalamus, thalamo-cortical circuit, structural covariance network, MRI, liver-brain axis, imaging transcriptomics, cortical thickness, liver function, neuroimaging, Allen Human Brain Atlas